Evidence map›Paper›PMID 28181685›Full record

ArticleThe Prostate2017

Effects of Estrogen Receptor β Stimulation in a Rat Model of Non-Bacterial Prostatic Inflammation.

Shinsuke Mizoguchi, Kenichi Mori, Zhou Wang, Teresa Liu, Yasuhito Funahashi, Fuminori Sato, Donald B DeFranco, Naoki Yoshimura, Hiromitsu Mimata

Open access · greenAbstract read
In one paragraph

Article in The Prostate, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. A uropathogenicAmerican journal of physiology. Renal physiology · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Is TRPA1International journal of molecular sciences · 2019
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Shinsuke MizoguchiDepartment of Urology, Oita University Graduate School of Medicine, Yufu, Japan.
Kenichi MoriDepartment of Urology, Oita University Graduate School of Medicine, Yufu, Japan.
Zhou WangDepartment of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Teresa LiuDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Yasuhito FunahashiDepartment of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Fuminori SatoDepartment of Urology, Oita University Graduate School of Medicine, Yufu, Japan.
Donald B DeFrancoDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Naoki YoshimuraDepartment of Urology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Hiromitsu MimataDepartment of Urology, Oita University Graduate School of Medicine, Yufu, Japan.
University of Pittsburgh · USOita University · JP

Funding

University of Pittsburgh O'Brien Cooperative Research Center ProgramU54DK112079 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DEFRANCO, DONALD B · 2016 to 2020
$6.5M
NIDDK NIH HHS U54 DK112079
6 · The paper itself

Abstract

backgroundThere is increasing evidence showing that chronic non-bacterial prostatic inflammation is involved in the pathogenesis of benign prostatic hyperplasia (BPH) and male lower urinary tract symptoms (LUTS). It has also been reported that estrogen receptor β (ERβ) could have an immunoprotective role in prostatic tissue. Therefore, we investigated the effect of ERβ-activation on not only prostatic inflammation, but also bladder overactive conditions in a rat model with nonbacterial prostatic inflammation.

methodsMale Sprague-Dawley rats (8 weeks, n = 15) were divided into three groups: sham-saline group (n = 5), formalin-vehicle group (n = 5), and formalin-treatment group (n = 5). The sham-saline group had sham operation and 50 μl normal saline injected into each ventral lobe of the prostate. The formalin-vehicle group had 50 μl 5% formalin injection into bilateral ventral lobes of the prostate. The formalin-treatment group was treated with 3α-Adiol (a selective ERβ agonist precursor) at a dose of 3 mg/kg daily from 2 days before induction of prostatic inflammation, whereas formalin-vehicle rats received vehicle (olive oil). In each group, conscious cystometry was performed on day 28 after intraprostatic formalin injection or sham treatment. After cystometry, the bladder and prostate were harvested for evaluation of mRNA expression and histological analysis.

resultsIn cystometric investigation, the mean number of non-voiding contractions was significantly greater and voiding intervals were significantly shorter in formalin-vehicle rats than those in sham-saline rats (P < 0.05). In RT-qPCR analysis, mRNA expression of NGF, P2X2, and TRPA1 receptors was significantly increased in the bladder mucosa, and mRNA expression of TNF-α, iNOS and COX2 in the ventral lobes of prostate was significantly increased in formalin-vehicle rats compared with sham-saline rats (P < 0.05). In addition, relative mRNA expression ratio of ERβ to ERα (ERβ/ERα) in the ventral lobes of prostate was significantly decreased in formalin-vehicle rats compared with sham-saline rats (P < 0.05). These changes were ameliorated by 3α-Adiol administration in formalin-treatment rats.

conclusionsThese results indicate that ERβ activation by 3α-Adiol administration, which normalized the ERβ/ERα expression ratio in the prostate, can improve not only prostatic inflammation, but also bladder overactivity. Therefore, ERβ agonists might be useful for treating irritative bladder symptoms in patients with symptomatic BPH associated with prostatic inflammation. Prostate 77:803-811, 2017. © 2017 Wiley Periodicals, Inc.

Indexed as

Estrogen Receptor betaLower Urinary Tract SymptomsProstatic HyperplasiaProstatitisAndrostane-3,17-diolAnimalsEstrogensMaleProstateProtective FactorsRatsRats, Sprague-DawleyTreatment OutcomeTumor Necrosis Factor-alphaUrinary BladderUrodynamicsAndrostane-3,17-diolEstrogen Receptor betaEstrogensTumor Necrosis Factor-alpha3α-Adiolestrogen receptorinflammationprostate

Identifiers

PMID28181685
PMCPMC5968815
OpenAlexW2587527633

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.